Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$93.70 USD
-3.30 (-3.40%)
Updated Jun 7, 2024 01:23 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Zealand Pharma AS falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 167 | 227 | 193 | 207 |
Receivables | NA | 19 | 18 | 9 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 19 | 10 | 0 |
Other Current Assets | NA | 0 | 10 | 5 | 5 |
Total Current Assets | NA | 186 | 274 | 218 | 214 |
Net Property & Equipment | NA | 7 | 14 | 13 | 6 |
Investments & Advances | NA | 5 | 6 | 8 | 7 |
Other Non-Current Assets | NA | 3 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 2 | 1 | 0 |
Intangibles | NA | 0 | 9 | 9 | 0 |
Deposits & Other Assets | NA | 0 | 3 | 2 | 0 |
Total Assets | NA | 218 | 329 | 270 | 240 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 26 | 10 | 11 | 9 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 5 | 0 |
Other Current Liabilities | NA | 0 | 41 | 37 | 19 |
Total Current Liabilities | NA | 28 | 53 | 54 | 29 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 2 | 7 | 13 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 57 | 103 | 18 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 3 | 3 | 0 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 103 | 181 | 82 | 53 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 7 | 7 | 6 | 5 |
Capital Surplus | NA | 0 | 676 | 532 | 397 |
Retained Earnings | NA | 106 | -526 | -351 | -216 |
Other Equity | NA | 2 | 2 | 1 | 0 |
Treasury Stock | NA | 0 | 11 | 0 | 0 |
Total Shareholder's Equity | NA | 116 | 148 | 188 | 186 |
Total Liabilities & Shareholder's Equity | NA | 218 | 329 | 270 | 240 |
Total Common Equity | 0 | 116 | 148 | 188 | 186 |
Shares Outstanding | 51.50 | 51.50 | NA | 35.80 | 35.80 |
Book Value Per Share | 0.00 | 2.24 | 0.00 | 5.26 | 5.20 |
Fiscal Year End for Zealand Pharma AS falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 231 | 247 | 144 |
Receivables | NA | NA | 54 | 20 | 18 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 2 | 2 | 1 |
Other Current Assets | NA | NA | 0 | 0 | 0 |
Total Current Assets | NA | NA | 287 | 269 | 163 |
Net Property & Equipment | NA | NA | 7 | 7 | 7 |
Investments & Advances | NA | NA | 3 | 3 | 3 |
Other Non-Current Assets | NA | NA | 3 | 3 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | NA | 1 | 0 | 0 |
Deposits & Other Assets | NA | NA | 0 | 0 | 3 |
Total Assets | NA | NA | 318 | 299 | 193 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | 0 | 0 |
Accounts Payable | NA | NA | 35 | 27 | 20 |
Current Portion Long-Term Debt | NA | NA | 0 | 0 | 0 |
Current Portion Capital Leases | NA | NA | 0 | 0 | 0 |
Accrued Expenses | NA | NA | 0 | 0 | 0 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | NA | 0 | 0 | 0 |
Total Current Liabilities | NA | NA | 38 | 29 | 22 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | NA | 0 | 0 | 57 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 3 | 3 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | NA | 52 | 47 | 96 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | NA | 9 | 9 | 7 |
Capital Surplus | NA | NA | 0 | 0 | 0 |
Retained Earnings | NA | NA | 255 | 241 | 87 |
Other Equity | NA | NA | 2 | 3 | 3 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | NA | 265 | 252 | 97 |
Total Liabilities & Shareholder's Equity | NA | NA | 318 | 299 | 193 |
Total Common Equity | 0 | 0 | 265 | 252 | 97 |
Shares Outstanding | 51.50 | 51.50 | 51.50 | 51.50 | 51.50 |
Book Value Per Share | 0.00 | 0.00 | 5.15 | 4.90 | 1.88 |